Here’s the link for the original South Korean article showing even more positive results for patients when the Ocata technique was used. This is a much smaller study with only four people, and I think the real value is that it supports the original results in the Lancet. There were two AMD and two SMD patients, and when I read the full article, I could see that all of them had improvements. Three were very significant (vision improved 50%, 100% (twice as good, and I can never remember if that should be 100% or 200%), and 1300% improvement– yes, vision that was thirteen times better than before the study!
The fourth person wasn’t considered to have significant improvement, but I’m not so sure that I would agree. Their vision went from being able to read one letter to two, and when your vision is that bad to start with, any improvement helps.
Anyway… I highly recommend reading the whole article. The complete pdf if available for free, which is usually not the case– so take advantage of it!
Treatment of Macular Degeneration Using Embryonic Stem Cell-Derived Retinal Pigment Epithelium: Preliminary Results in Asian Patients
Posted in Great News
Tagged amd, asian patients, CHA, cure, Hyun-Ju Kim, ISSCR, Jae Ho Lee, Jinjung Choi, Kyung-Mi Park, Lucian V. Del Priore, Macular Degeneration, ocata, robert lanza, SMD, So Young Chong, South Korea, stem cell reports, stem cells, Sung Han Shim, Won Kyung Song
YES! These are the results we’ve been waiting for from CHA in So. Korea. They are great, and they 100% support the Lancet results from Ocata’s own trials. The thing that really impresses me about the CHA results is that just like Ocata’s, they were published in a peer-reviewed journal instead of being released through a company announcement. I have to say, I’m kind of over company announcements. (Remember when StemCells Inc did that??) Anyone can announce anything. I can announce that I just won Powerball. That doesn’t make it true! An article in a peer-reviewed journal is the gold standard.
Anyway, here’s a snippet, although you really need to go the link:
Here’s a cogent, intelligent, and rational comment to the news below:
3458qu9fqu4589q3u-!!!!! OMG I DON’T EVEN. O.o.
This moment has been brought to you by the Department of Medical Miracles to Come. 🙂
THIS IS WHAT WE’VE BEEN WAITING FOR!!! It’s the OFFICIAL announcement! Ocata can now start the second trial! They have pivotal trial status from the European Medicines Agency! This means that they can start marketing the drug after the next trial is over! It would be the FIRST stem cell based drug approved since 1956! Yes, I really DO think that we need all of these exclamation points!!!
Capslock? What capslock? 😉
Ahem. Anyway, check it out. 🙂
Ocata’s Press Release on the Completion of Phase I/II of SMD Trials